New hope for brain damage after cancer radiation
NCT ID NCT06888817
Summary
This study aims to find the best first treatment for brain swelling (radiation necrosis) that can occur after radiation therapy for brain tumors or metastases. It will compare a drug called bevacizumab, given by IV every three weeks, against the standard steroid pills (dexamethasone) over 12 weeks. The goal is to see which treatment better improves patients' daily function and quality of life while reducing the need for steroids.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIATION NECROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam University Medical Centers, location VUmc and AMC
RECRUITINGAmsterdam, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Haaglanden Medical Center
RECRUITINGThe Hague, 2262 BA Leidschendam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Leiden University Medical Center
RECRUITINGLeiden, 2333 ZA Leiden, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Netherlands Cancer Institute - Antoni van Leeuwenhoek
RECRUITINGAmsterdam, 1066 CX Amsterdam, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Medical Center Utrecht
RECRUITINGUtrecht, 3584 CX Utrecht, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.